Vera Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(a) None.
(b)None.
(c) The following table describes for the quarterly period covered by this report each trading arrangement for the purchase or sale of Company securities adopted, modified or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a “Rule 10b5-1 trading arrangement,” or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):
| Type of Trading Arrangement | ||||||||
| Name | Position | Action | Adoption/ TerminationDate | Rule 10b5-1* | Non-Rule 10b5-1** | Total Shares of Class A Common Stock to be Sold*** | Total Shares of Class A Common Stock to be Purchased | Expiration Date |
|---|---|---|---|---|---|---|---|---|
| Marshall Fordyce | Chief Executive Officer | Adoption | January 9, 2026 | X | Up to 432,826 shares(1) | N/A | March 31, 2027 | |
| Robert Brenner | Chief Medical Officer | Adoption | January 9, 2026 | X | Up to 91,200 shares | N/A | December 17, 2026 |
|---|---|---|---|---|---|---|---|
| Sean Grant | Chief Financial Officer | Adoption | January 9, 2026 | X | Up to 53,276 shares | N/A | December 17, 2026 |
| * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. | |||||||
| ** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. | |||||||
| *** Represents the maximum number of shares that may be sold pursuant to the 10b5-1 trading arrangement. The number of shares to be sold is dependent on the satisfaction of certain conditions as set forth in the written plan. | |||||||
(1)The shares that may be sold under the Rule 10b5-1 trading plan may be reduced by the number of shares sold to satisfy tax withholding obligations upon vesting of certain restricted stock units covered by the plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.